Letters: End the false economy of generic prescribing

The warning of adverse events linked to the use of generic drug alendronate in your article 'Side-effects of NICE-backed drug "wipe out cost savings"' (GP, 19 September) comes from a consultant physician.

It seems that NICE is not nice nor a patient-friendly regulatory body any more.

The UK is adapting policy to save money at the expense of patients' misery. Surely NICE can find a sensible alternative to this ridiculous false economy.

GPs are all too well aware of the adverse effects patients suffer from not only generic alendronate, but also many other cheap products pushed into the system. The incentive scheme is a failure and it is about time we reverted to prescribing branded, clean and well-tested pharmaceutical products ethically.

Dr Hari Nawal, Bedford.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in